Cannabis Health/LinkedIn
Mar 9, 2026, 10:16
Ananda Pharma Cleared to Launch Phase 2 Trial for Endometriosis Pain Treatment – Cannabis Health
Cannabis Health shared a post on LinkedIn:
“Ananda Pharma Ltd has cleared the final regulatory hurdle needed to begin its ENDOCAN Phase 2 clinical trial in women with endometriosis-associated pain.
The company has received approval from the MHRA and NHS Health Research Authority to commence dosing of its proprietary MRX1 CBD oral solution.
Melissa Sturgess, CEO of Ananda Pharma, said: ‘The reason this study is different is that we are using a product that could go all the way through to regulatory approval and be able to be prescribed by a doctor on the NHS.’ ”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Apr 17, 2026, 04:19WHO Raises Alarm Over Global Burden of Child Marriage
-
Apr 17, 2026, 04:11Sign Up for Our Latest BFS Insights Webinar – British Fertility Society
-
Apr 17, 2026, 03:43Chantelle Pereira: Endometriosis Paper Highlights Diagnostic Delays and Gaps in Patient Care
-
Apr 17, 2026, 03:35Tal Varsano: Plasma Proteomic Signature of the Human Menstrual Cycle
-
Apr 17, 2026, 03:30Vacancy for a Friendly Senior Embryologist in Berlin, Germany – ESHRE
-
Apr 17, 2026, 03:05Clinical Study Supports Continued IVF After Unsuccessful First Transfer – RBMO
-
Apr 17, 2026, 02:57Standing Together for Black Maternal Health Week – ACOG
-
Apr 16, 2026, 17:24No Difference Between Natural and Artificial Cycles in Endometrium Cases – RBMO
-
Apr 16, 2026, 17:20Marco Zaccaria: Recognizing Innovation in Adenomyosis Treatment